Frontiers in immunology · 2026
Prevalence of female sexual dysfunction among women with systemic lupus erythematosus: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dai Xiaowei, Ding Hongxiang, Mao Dikai, Huang Jiaguo
Аннотация
BACKGROUND: The prevalence of female sexual dysfunction (FSD) among women with systemic lupus erythematosus (SLE) is inconsistent, and whether SLE is a risk factor for FSD among women remains controversial. Therefore, this study aimed to conduct a systematic review and meta-analysis to estimate the prevalence of FSD among women with SLE and further explore the association between SLE and FSD.
METHODS: Literature on the prevalence of FSD among women with SLE was retrieved from PubMed, Web of Science, Cochrane Library, and Embase databases from inception to July 1, 2025. The pooled prevalence was calculated using a random-effects model for the meta-analysis. The Cochran Q and I 2 tests were employed to examine heterogeneity among the studies, while subgroup analyses and meta-regression were conducted to identify potential sources of heterogeneity.
RESULTS: This meta-analysis included 13 studies involving 1,511 women with SLE and 2,246 healthy controls. The pooled prevalence of FSD among women with SLE was 58.8% (95% confidence interval [CI], 0.461-0.716). Compared with the healthy control group, women with SLE had a significantly increased risk of FSD (odds ratio, 2.64; 95% CI, 1.27-5.47).
CONCLUSION: This systematic review and meta-analysis demonstrated a high prevalence of FSD among women with SLE and a significant association between SLE and an increased risk of FSD.
SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2025-7-0092/,identifier 202570092.
METHODS: Literature on the prevalence of FSD among women with SLE was retrieved from PubMed, Web of Science, Cochrane Library, and Embase databases from inception to July 1, 2025. The pooled prevalence was calculated using a random-effects model for the meta-analysis. The Cochran Q and I 2 tests were employed to examine heterogeneity among the studies, while subgroup analyses and meta-regression were conducted to identify potential sources of heterogeneity.
RESULTS: This meta-analysis included 13 studies involving 1,511 women with SLE and 2,246 healthy controls. The pooled prevalence of FSD among women with SLE was 58.8% (95% confidence interval [CI], 0.461-0.716). Compared with the healthy control group, women with SLE had a significantly increased risk of FSD (odds ratio, 2.64; 95% CI, 1.27-5.47).
CONCLUSION: This systematic review and meta-analysis demonstrated a high prevalence of FSD among women with SLE and a significant association between SLE and an increased risk of FSD.
SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2025-7-0092/,identifier 202570092.